Y Intercept Hong Kong Ltd Invests $452,000 in Theravance Biopharma, Inc. $TBPH

Y Intercept Hong Kong Ltd bought a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 40,943 shares of the biopharmaceutical company’s stock, valued at approximately $452,000. Y Intercept Hong Kong Ltd owned 0.08% of Theravance Biopharma as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its position in shares of Theravance Biopharma by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 1,720 shares during the last quarter. Tabor Asset Management LP purchased a new stake in Theravance Biopharma during the first quarter valued at about $135,000. Brookwood Investment Group LLC purchased a new position in shares of Theravance Biopharma in the first quarter worth approximately $188,000. GSA Capital Partners LLP raised its holdings in shares of Theravance Biopharma by 11.9% during the first quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company’s stock valued at $1,628,000 after acquiring an additional 19,363 shares during the period. Finally, XTX Topco Ltd lifted its position in shares of Theravance Biopharma by 20.8% in the 1st quarter. XTX Topco Ltd now owns 19,759 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,403 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Finally, B. Riley started coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a “buy” rating and a $28.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Theravance Biopharma has an average rating of “Buy” and a consensus price target of $23.00.

Theravance Biopharma Trading Down 0.5%

NASDAQ:TBPH opened at $14.87 on Friday. The firm has a market capitalization of $748.85 million, a price-to-earnings ratio of 61.96 and a beta of 0.07. The business’s 50-day moving average price is $14.18 and its two-hundred day moving average price is $12.02. Theravance Biopharma, Inc. has a 1-year low of $7.90 and a 1-year high of $15.34.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.